Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.

Item
http://www.wikidata.org/entity/Q33387924
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesEnzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysisA pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms.Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials.Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies.The place of pemetrexed in the management of non-small-cell lung cancer patients.Pemetrexed for the treatment of non-small cell lung cancer.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials.Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
P2860

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.

Item
http://www.wikidata.org/entity/Q33387924
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@ast
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@en
type
label
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@ast
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@en
prefLabel
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@ast
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Phase II, double-blinded, rand ...... ed non-small cell lung cancer.
@en
P2093
P304
P31
P356
10.1097/JTO.0B013E3181CEE24F
P433
P478
P50
P577
P698